A NEW CONCEPT ON PREVENTION AND CURE OF DISEASES BY A BROAD SPECTRUM PROTEASE INHIBITOR (A2M)

Different types of proteases may play influential rolesacross a spectrum of diseases. Correspondingly, protease inhibitors have been known to play crucial roles in the patho-physiology of diseases. We hypothesize the activity of the broad spectrum protease inhibitor, alpha-2-macroglobulin (A2M) may hold unexplored roles in diseases as well. Clinically measuring levels of variant proteases in combination with the monitoring of A2M, in plasma, can be a novel approach to further our understandingof diseases related to protease activity. There is evidence showingadministration of purified human A2M to
animal models with bacteria induced septic shock usingPseudomonas aeruginosaresulted in the reversal of the pathological effect. In addition, recent evidence has also shown the beneficial effectsof treatment with autologous A2M in post-traumatic osteoarthritis patients. We have measured levels of protease (trypsin) and A2Mduring the chronic ill patients (n=31) and compared their values to normal healthy donors (n=31). Our results show protease activity in blood went up from 516.16 ±17.17 to5021.22 ± 61.63 mg/ml (p<0.001 ) and A2M levels went down from 2013.30 ± 52.00 to 487.64 ± 9.70
(p<0.001). All critically ill patients showed a significant increase in protease levels and also a significant decrease in protease inhibitor (A2M). These results further support evidence suggesting an inverse relationship taken on by protease and protease inhibitors in severe to terminal cases